lobular carcinoma

Summary

Summary: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.

Top Publications

  1. Rakha E, Patel A, Powe D, Benhasouna A, Green A, Lambros M, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol. 2010;34:1472-9 pubmed publisher
    Although virtually all cases of lobular carcinoma in situ lack E-cadherin expression, a proportion of morphologically typical invasive lobular carcinomas (ILCs) retain its expression...
  2. Moran M, Yang Q, Haffty B. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expressio. Breast J. 2009;15:571-8 pubmed publisher
    ..Future investigations of chemo-preventive strategies to decrease contralateral breast cancers are warranted...
  3. Bharat A, Gao F, Margenthaler J. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg. 2009;198:516-9 pubmed publisher
    ..The aim of this study was to investigate the clinical characteristics associated with invasive lobular cancer (ILC) and mixed invasive ductal cancer (IDC) and ILC compared with IDC...
  4. Chen Y, Hwang E, Roy R, Devries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33:1683-94 pubmed publisher
    The clinical, pathologic, and molecular features of pleomorphic lobular carcinoma in situ (PLCIS) and the relationship of PLCIS to classic LCIS (CLCIS) are poorly defined...
  5. Rosa M, Mohammadi A, Masood S. Lobular carcinoma of the breast with extracellular mucin: new variant of mucin-producing carcinomas?. Pathol Int. 2009;59:405-9 pubmed publisher
    ..To the best of the authors' knowledge, infiltrating lobular carcinoma displaying extracellular mucin has not been described in the literature...
  6. Vargas A, Lakhani S, Simpson P. Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. Future Oncol. 2009;5:233-43 pubmed publisher
    Pleomorphic lobular carcinoma of the breast is a recently described morphological variant of classic invasive lobular carcinoma with an aggressive behavior...
  7. Choi Y, Pinto M, Hao L, Riba A. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. Mod Pathol. 2008;21:1224-37 pubmed publisher
    The distinction between lobular neoplasia and infiltrating lobular carcinoma from ductal neoplasia and infiltrating duct carcinoma with equivocal histologic features may present a challenge as this distinction has important therapeutic ..
  8. Hwang H, Barke L, Mendelson E, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol. 2008;21:1208-16 pubmed publisher
    ..We reviewed 333 cases of atypical lobular hyperplasia or lobular carcinoma in situ without ductal carcinoma in situ or invasive carcinoma diagnosed in core biopsies from 1996 to 2006...
  9. Buchanan C, Flynn L, Murray M, Darvishian F, Cranor M, Fey J, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity?. J Surg Oncol. 2008;98:314-7 pubmed publisher
    Attempts to define the clinical behavior of pleomorphic lobular carcinoma (PLC) have been limited to small series, and clinical management strategies have yet to be established...

More Information

Publications69

  1. Orvieto E, Maiorano E, Bottiglieri L, Maisonneuve P, Rotmensz N, Galimberti V, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer. 2008;113:1511-20 pubmed publisher
    Although invasive lobular carcinoma (ILC) is the second most common histotype of breast cancer, the prognostic implications of its clinicopathologic characteristics remain controversial.
  2. Ciocca R, Li T, Freedman G, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 2008;15:2263-71 pubmed publisher
    b>Lobular carcinoma in situ (LCIS) is known to be a risk factor for the development of invasive breast cancer. Debate continues as to whether LCIS is also a precursor lesion...
  3. Cao D, Polyak K, Halushka M, Nassar H, Kouprina N, Iacobuzio Donahue C, et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res. 2008;10:R91 pubmed publisher
    Although lobular carcinoma in situ (LCIS) has traditionally been viewed as a marker of breast cancer risk, recent clinical, pathological and genetic analyses have supported the concept that LCIS is a low risk, direct precursor of ..
  4. Seniski G, Camargo A, Ierardi D, Ramos E, Grochoski M, Ribeiro E, et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009;9:80 pubmed publisher
    ..This seems to correlate with tumour progression and metastasis in breast cancer. In this study, we explored the involvement of ADAM33, another ADAM family member, in breast cancer...
  5. Boughey J, Wagner J, Garrett B, Harker L, Middleton L, Babiera G, et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009;16:1606-11 pubmed publisher
    Patients with invasive lobular carcinoma (ILC) experience a lower pathological complete response rate to neoadjuvant chemotherapy than patients with invasive ductal carcinoma...
  6. Green A, Young P, Krivinskas S, Rakha E, Claire Paish E, Powe D, et al. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. Histopathology. 2009;54:419-27 pubmed publisher
    To determine the status of oestrogen receptor (ER) subtypes (ERalpha and ERbeta) in lobular carcinoma in situ (LCIS) of the breast.
  7. Anwar I, Down S, Rizvi S, Farooq N, Burger A, Morgan A, et al. Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease?. Int J Surg. 2010;8:346-52 pubmed publisher
    The surgical treatment of patients with invasive lobular carcinoma is still controversial due to its different clinical and pathological features...
  8. Balja M, Vrdoljak D, Stanec M, Sitic S, Supić D, Knezevic F. Rectal metastasis from lobular carcinoma of the breast: a case report. Coll Antropol. 2010;34:719-21 pubmed
    ..We present a case of 83-year old woman with rectal metastesis from ILC seven years after surgery of primary tumor...
  9. Horvath J, Barnett G, Jimenez R, Young D, Povoski S. Comparison of intraoperative frozen section analysis for sentinel lymph node biopsy during breast cancer surgery for invasive lobular carcinoma and invasive ductal carcinoma. World J Surg Oncol. 2009;7:34 pubmed publisher
    ..of intraoperative frozen section analysis for confirming metastatic involvement of SLNs in cases of invasive lobular carcinoma (ILC) versus that of invasive ductal carcinoma (IDC) has generated controversy secondary to a frequently low-..
  10. Laser J, Cangiarella J, Singh B, Melamed J, Chiriboga L, Yee H, et al. Invasive lobular carcinoma of the breast: role of endothelial lymphatic marker D2-40. Ann Clin Lab Sci. 2008;38:99-104 pubmed
    ..LVI is infrequently encountered in invasive lobular carcinoma when compared to invasive ductal carcinoma...
  11. Pestalozzi B, Zahrieh D, Mallon E, Gusterson B, Price K, Gelber R, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26:3006-14 pubmed publisher
    To determine how patients with infiltrating lobular carcinoma (ILC) differ from patients with the more common infiltrating ductal carcinoma (IDC) with regard to patient and tumor factors, local treatment, and patterns of recurrence.
  12. Tan L, Giri D, Hummer A, Panageas K, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803-9 pubmed publisher
    ..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
  13. Jobsen J, Riemersma S, Van Der Palen J, Ong F, Jonkman A, Struikmans H. The impact of margin status in breast-conserving therapy for lobular carcinoma is age related. Eur J Surg Oncol. 2010;36:176-81 pubmed publisher
    The aim is to look at the impact of margin status and outcome of invasive lobular carcinoma (ILC) treated with breast-conserving therapy (BCT).
  14. Lopez J, Bassett L. Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics. 2009;29:165-76 pubmed publisher
    The reported prevalence of invasive lobular carcinoma (ILC) is variable, with more recent studies indicating that ILC accounts for 10%-15% of all invasive breast carcinomas...
  15. Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe J, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene. 2008;27:5359-72 pubmed publisher
    ..Although ILCs and IDCs share common alterations, our data show that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways...
  16. Mann R, Loo C, Wobbes T, Bult P, Barentsz J, Gilhuijs K, et al. The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2010;119:415-22 pubmed publisher
    Re-excision rates after breast conserving surgery(BCS) of invasive lobular carcinoma (ILC) are high.Preoperative breast MRI has the potential to reduce re-excision rates, but may lead to an increased rate of mastectomies...
  17. Sabate J, Clotet M, Torrubia S, Guerrero R, Pineda R, Lerma E, et al. Localized amyloidosis of the breast associated with invasive lobular carcinoma. Br J Radiol. 2008;81:e252-4 pubmed publisher
    Here a case of primary amyloidosis of the breast associated with invasive lobular carcinoma is reported with a brief review of the most relevant clinical, radiological and pathological features...
  18. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-51 pubmed publisher
    ..We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen...
  19. Patil D, Susnik B. Keratin immunohistochemistry does not contribute to correct lymph node staging in patients with invasive lobular carcinoma. Hum Pathol. 2008;39:1011-7 pubmed publisher
    ..improves rate of detecting sentinel lymph node metastases and is needed for adequate staging in invasive lobular carcinoma. Our study evaluates the use of cytokeratin immunohistochemistry in detecting sentinel lymph node metastases ..
  20. Simpson P, Reis Filho J, Lambros M, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215:231-44 pubmed publisher
    ..lobular carcinomas (PLC) of the breast display histological features associated with classic invasive lobular carcinoma (ILC), yet they also exhibit more conspicuous nuclear atypia and pleomorphism, and an aggressive clinical ..
  21. Brandt S, Young G, Hoda S. The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol. 2008;15:140-6 pubmed publisher
    The histologic triad of tubular carcinoma (TC), columnar cell lesion (CCL), and lobular carcinoma in situ (LCIS) has been recognized, but has not yet been fully characterized...
  22. Brem R, Ioffe M, Rapelyea J, Yost K, Weigert J, Bertrand M, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol. 2009;192:379-83 pubmed publisher
    The objective of our study was to compare the sensitivity of mammography, sonography, MRI, and breast-specific gamma imaging (BSGI) in the detection of invasive lobular carcinoma.
  23. Honda Y, Iyama K. Malignant adenomyoepithelioma of the breast combined with invasive lobular carcinoma. Pathol Int. 2009;59:179-84 pubmed publisher
    ..is the first case of malignant adenomyoepithelioma (malignant AME) of the breast combined with invasive lobular carcinoma (ILC) in a 53-year-old woman...
  24. Mann R. The effectiveness of MR imaging in the assessment of invasive lobular carcinoma of the breast. Magn Reson Imaging Clin N Am. 2010;18:259-76, ix pubmed publisher
    Invasive lobular carcinoma (ILC) of the breast is, due to its diffuse infiltrative growth pattern, a diagnostic challenge. Even in retrospect, only up to 80% are visible at mammography...
  25. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat J. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 2008;19:73-80 pubmed
    ..Our study demonstrates that (i) ErbB/HER ligands, including BTC and EREG, are expressed in most breast cancers; and (ii) TGFalpha, HB-EGF and NRG2 high expressions are related to the biological aggressiveness of the tumours. ..
  26. Karabakhtsian R, Johnson R, Sumkin J, Dabbs D. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. 2007;31:717-23 pubmed
    ..numbers upstaged from core biopsies were as follows: atypical lobular hyperplasia (ALH) 4/52 (8%), mixed ALH/lobular carcinoma in situ (LCIS) 1/9 (10%), and pure LCIS 3/16 (19%)...
  27. Green A, Krivinskas S, Young P, Rakha E, Paish E, Powe D, et al. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2009;113:59-66 pubmed publisher
    Loss of the chromosomal material at 16q is the most frequent genetic event in invasive and in situ (LCIS) lobular carcinoma of the breast...
  28. Glass A, Lacey J, Carreon J, Hoover R. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152-61 pubmed
    ..From 1980 through 2006, quantitative and qualitative trends in breast cancer incidence rates, particularly for ER+ tumors, parallel major changes in patterns of mammography screening and use of menopausal hormone therapy. ..
  29. Gonzalez Angulo A, Sahin A, Krishnamurthy S, Yang Y, Kau S, Hortobagyi G, et al. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer. 2006;7:396-400 pubmed
    ..expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers.
  30. Mann R, Veltman J, Barentsz J, Wobbes T, Blickman J, Boetes C. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol. 2008;34:135-42 pubmed
    Invasive lobular carcinoma of the breast (ILC) is known to be substantially underestimated by mammography, which makes correct planning of treatment difficult. MRI has been proposed as a valuable adjunct to mammography...
  31. Abdel Fatah T, Powe D, Hodi Z, Reis Filho J, Lee A, Ellis I. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513-23 pubmed publisher
    ..Our findings support the concept that progression of LNGBC to HNGBC (basal-like or HER2+) phenotype is an unlikely biologic phenomenon. ..
  32. Esserman L, Lamea L, Tanev S, Poppiti R. Should the extent of lobular neoplasia on core biopsy influence the decision for excision?. Breast J. 2007;13:55-61 pubmed
    ..LN was defined to include both atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) and was categorized as focal or diffuse...
  33. Chan S, LaVigne K, Port E, Fey J, Brogi E, Borgen P, et al. Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?. Ann Surg. 2008;247:143-9 pubmed
  34. Piechocki M, Dibbley S, Lonardo F, Yoo G. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer. 2008;122:1722-9 pubmed
    ..These studies demonstrate the critical role of HER2 signal transduction in the onset and progression of HER2/neu-dependent breast cancer and suggest a role for specific inhibitors to prevent the outgrowth of early hyperplastic disease...
  35. Yoder B, Wilkinson E, Massoll N. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J. 2007;13:172-9 pubmed
    ..The goal of this review is to present what is currently known about the molecular profiles of infiltrating ductal and lobular carcinoma and how they relate to conventional histopathology and biologic behavior.
  36. Rakha E, El Sayed M, Powe D, Green A, Habashy H, Grainge M, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44:73-83 pubmed
    Invasive lobular carcinoma (ILC) comprises approximately 5-15% of breast cancers and appears to have a distinct biology...
  37. van Dam P, van Dam P, Verkinderen L, Vermeulen P, Deckers F, Dirix L. Robotic-assisted laparoscopic cytoreductive surgery for lobular carcinoma of the breast metastatic to the ovaries. J Minim Invasive Gynecol. 2007;14:746-9 pubmed
    ..Histologic examination showed strongly estrogen receptor-positive metastatic lobular carcinoma of the breast in both ovaries and fallopian tubes...
  38. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer. 2007;14:549-67 pubmed
    ..the association between the use of hormone replacement therapy (HRT) and a higher risk of both invasive lobular carcinoma (ILC) and invasive ductal-lobular mixed carcinoma (IDLC)...
  39. Jayasinghe U, Bilous A, Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?. Breast J. 2007;13:479-85 pubmed
    ..of patients with breast cancer have compared survival of invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) with contradictory results...
  40. Caramella T, Chapellier C, Ettore F, Raoust I, Chamorey E, Balu Maestro C. Value of MRI in the surgical planning of invasive lobular breast carcinoma: a prospective and a retrospective study of 57 cases: comparison with physical examination, conventional imaging, and histology. Clin Imaging. 2007;31:155-61 pubmed
    The objective of this study was to determine the value of magnetic resonance imaging (MRI) for the surgical planning of invasive lobular carcinoma (ILC)-a diagnostic challenge for radiologists.
  41. Fadare O, Wang S, Hileeto D. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?. Hum Pathol. 2008;39:331-6 pubmed publisher
    ..Future studies are required to define the prognostic significance of CK5/6 expression in ILCs...
  42. Valdes E, Boolbol S, Ali I, Feldman S, Cohen J. Intraoperative touch preparation cytology for margin assessment in breast-conservation surgery: does it work for lobular carcinoma?. Ann Surg Oncol. 2007;14:2940-5 pubmed
    ..Invasive lobular carcinoma (ILC) accounts for 10% to 15% of all breast cancers. Obtaining clear margins in ILC can be more challenging...
  43. Dabbs D, Kaplai M, Chivukula M, Kanbour A, Kanbour Shakir A, Carter G. The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2007;15:260-6 pubmed
    Pleomorphic lobular carcinoma of the breast is a high nuclear grade variant of lobular carcinoma. E-cadherin, a tumor-invasion suppressor gene, codes for a transmembrane protein that functions in intercellular adhesion...
  44. Erhan Y, Zekioglu O, Erhan Y. Invasive lobular carcinoma of the male breast. Can J Surg. 2006;49:365-6 pubmed
  45. Kasashima S, Kawashima A, Zen Y, Ozaki S, Kobayashi M, Tsujibata A, et al. Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast. Virchows Arch. 2007;450:397-403 pubmed
    ..We selected eight cases of histiocytoid features of invasive lobular carcinoma (HLC) and compared with 14 age- and tumor size-matched cases of classical invasive lobular carcinoma (CLC)...
  46. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55 pubmed
    ..The aim of our study was to identify gene expression profiles of IDC and ILC in relation to normal breast epithelial cells...
  47. Bollet M, Thibault F, Bouillon K, Meunier M, Sigal Zafrani B, Savignoni A, et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. Int J Radiat Oncol Biol Phys. 2007;69:13-8 pubmed
  48. Zaczek A, Wełnicka Jaśkiewicz M, Bielawski K, Jaskiewicz J, Badzio A, Olszewski W, et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol. 2008;134:271-9 pubmed
    ..The aim of the study was to analyze the occurrence of abnormal gene copy numbers of all HER oncogenes and to correlate these alterations to other clinicopathological variables in a consecutive series of 225 breast cancer patients...
  49. Mastracci T, Boulos F, Andrulis I, Lam W. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer. Breast Cancer Res. 2007;9:215 pubmed
    ..We highlight studies utilizing genomic approaches and describe how these investigations have furthered our understanding of the complexity of premalignant breast lesions...
  50. Mann R, Hoogeveen Y, Blickman J, Boetes C. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2008;107:1-14 pubmed
    The clinical diagnosis and management of invasive lobular carcinoma (ILC) of the breast presents difficulties. Magnetic resonance imaging (MRI) has been proposed as the imaging modality of choice for the evaluation of ILC...
  51. Reis Filho J, Simpson P, Turner N, Lambros M, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12:6652-62 pubmed
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  52. Turashvili G, Bouchal J, Ehrmann J, Fridman E, Skarda J, Kolar Z. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:59-64 pubmed
    ..The loss of E-cadherin expression has been suggested to be the most reliable marker for invasive lobular carcinoma. The aim of our study was to identify the diagnostic usefulness of novel markers in the differentiation of ..
  53. Goldstein N, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007;110:1687-96 pubmed
    ..In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups...
  54. Lehmann U, Hasemeier B, Christgen M, Muller M, Römermann D, Langer F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008;214:17-24 pubmed
    ..8). In conclusion, this study demonstrates that various microRNA genes are also affected by epigenetic inactivation due to aberrant hypermethylation and that this is an early and frequent event in breast cancer development...
  55. Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P, Sinn H. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat. 2008;107:331-5 pubmed
    b>Lobular carcinoma in situ (LCIS) of the breast is generally considered an indicator for a bilaterally increased risk of invasive breast cancer (IBC)...
  56. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008;10:R2 pubmed publisher
    ..However, the clinical outcome with regard to total HER receptor state remains largely unknown...
  57. Ayantunde A, Agrawal A, Parsons S, Welch N. Esophagogastric cancers secondary to a breast primary tumor do not require resection. World J Surg. 2007;31:1597-601 pubmed
    ..This study reviewed the clinicopathological features of esophagogastric secondary tumors from breast cancer...
  58. Nonni A, Zagouri F, Sergentanis T, Lazaris A, Patsouris E, Zografos G. Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. Virchows Arch. 2007;451:893-7 pubmed
    The designation lobular neoplasia (LN) of the breast includes atypical lobular hyperplasia and lobular carcinoma in situ. Estrogen receptors (ER) play a significant role in breast carcinogenesis...
  59. Dabbs D, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 2007;31:427-37 pubmed
    ..The proper distinction between atypical lobular hyperplasia, lobular carcinoma in situ and low-grade ductal carcinoma in situ is critical for patient management...
  60. Smitt M, Horst K. Association of clinical and pathologic variables with lumpectomy surgical margin status after preoperative diagnosis or excisional biopsy of invasive breast cancer. Ann Surg Oncol. 2007;14:1040-4 pubmed
    ..To evaluate the impact of preoperative diagnosis in obtaining negative lumpectomy margins...